Information To Support a Claim of Electromagnetic Compatibility of Electrically Powered Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availability, 67411-67412 [2015-27818]
Download as PDF
Federal Register / Vol. 80, No. 211 / Monday, November 2, 2015 / Notices
The draft guidance, when finalized, will
represent the Agency’s current thinking
on the design of BE studies to support
ANDAs for progesterone gel. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
10.115(g)(5)), to ensure that the Agency
considers your comment of this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by December 17,
2015.
ADDRESSES: You may submit comments
as follows:
II. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Dated: October 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–27816 Filed 10–30–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–D–3787]
Information To Support a Claim of
Electromagnetic Compatibility of
Electrically Powered Medical Devices;
Draft Guidance for Industry and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
asabaliauskas on DSK5VPTVN1PROD with NOTICES
ACTION:
Notice of availability.
SUMMARY: The Food and Drug
Administration (FDA or Agency) is
announcing the availability of the draft
guidance entitled ‘‘Information to
Support a Claim of Electromagnetic
Compatibility (EMC) of ElectricallyPowered Medical Devices.’’ This
guidance describes the types of
information that should be provided to
support a claim of electromagnetic
compatibility (EMC) in a premarket
submission for an electrically powered
medical device. Electromagnetic
disturbance is electronic product
radiation that may interfere with the
performance of an electrically powered
medical device in its intended
environment (i.e., cause an
electromagnetic interference (EMI)).
EMC assessment helps to ensure that a
device is able to function in its intended
environment without introducing
excessive electromagnetic disturbances
that might interfere with other devices.
This draft guidance is not final nor is it
in effect at this time.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
VerDate Sep<11>2014
18:55 Oct 30, 2015
Jkt 238001
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2015–D–3787 for ‘‘Information to
Support a Claim of Electromagnetic
Compatibility (EMC) of ElectricallyPowered Medical Devices.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
67411
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION’’. The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
An electronic copy of the guidance
document is available for download
from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the draft guidance
document entitled ‘‘Information to
Support a Claim of Electromagnetic
Compatibility (EMC) of ElectricallyPowered Medical Devices’’ to the Office
of the Center Director, Guidance and
Policy Development, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
E:\FR\FM\02NON1.SGM
02NON1
67412
Federal Register / Vol. 80, No. 211 / Monday, November 2, 2015 / Notices
FOR FURTHER INFORMATION CONTACT:
II. Significance of Guidance
Donald Witters, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave. Bldg. 62, Rm. 1130, Silver Spring,
MD 20993–0002, 301–796–2483.
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on information that should be provided
to support claims of electromagnetic
compatibility of electrically powered
medical devices. It does not establish
any rights for any person and is not
binding on FDA or the public. You can
use an alternative approach if it satisfies
the requirements of the applicable
statute and regulations.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
I. Background
FDA is announcing the availability of
a draft guidance to provide FDA’s
current thinking on the types of
information that should be provided in
a premarket submission to support a
claim of electromagnetic compatibility
for an electrically powered medical
device. EMI is a hazard with associated
risk for electrically powered medical
devices. EMC assessment can help to
ensure that the risks associated with
performance degradation of electrically
powered medical devices due to EMI are
adequately mitigated.
The draft guidance includes
information consistent with
specifications described in FDArecognized consensus national or
international standards for EMC such as
in the International Electrotechnical
Commission (IEC) 60601–1–2: Edition 3:
2007–03, Medical Electrical
Equipment—Part 1–2: General
Requirements for Basic Safety and
Essential Performance—Collateral
Standard: Electromagnetic
Compatibility—Requirements and Tests;
IEC 60601–1–2: Edition 4.0: 2014–01,
Medical Electrical Equipment, Part 1–2:
General Requirements for Basic Safety
and Essential Performance—Collateral
Standard: Electromagnetic
Disturbances—Requirements and Tests;
Association for the Advancement of
Medical Instrumentation (AAMI)/
American National Standards Institute
(ANSI)/IEC 60601–1–2: 2007/(R) 2012
Medical Electrical Equipment—Part 1–
2: General Requirements for Basic Safety
and Essential Performance—Collateral
Standard: Electromagnetic
Compatibility—Requirements and Tests;
and AAMI/ANSI/IEC 60601–1–2: 2014,
Medical Electrical Equipment—Part 1–
2: General Requirements for Basic Safety
and Essential Performance—Collateral
Standard: Electromagnetic
Disturbances—Requirements and Tests
Standards that sponsors and
manufacturers of electrically powered
medical devices often reference. This
draft guidance is intended to help
ensure that clear and consistent
information is provided in premarket
submissions regarding medical device
EMC and to facilitate the review of
submissions with EMC claims.
VerDate Sep<11>2014
18:55 Oct 30, 2015
Jkt 238001
III. Electronic Access
Persons interested in obtaining a copy
of the draft guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Information to Support a Claim of
Electromagnetic Compatibility (EMC) of
Electrically-Powered Medical Devices’’
may send an email request to CDRHGuidance@fda.hhs.gov to receive an
electronic copy of the document. Please
use the document number 1400057 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR part 814 have
been approved under OMB control
number 0910–0231. The collections of
information in 21 CFR part 807, subpart
E have been approved under OMB
control number 0910–0120. The
collections of information in 21 CFR
part 812 have been approved under
OMB control number 0910–0078. The
collections of information in 21 CFR
part 814, subpart H have been approved
under OMB control number 0910–0332.
The collections of information in
sections 520(m) and 515A of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
360j and 21 U.S.C. 360e–1, respectively)
and 613(b) of Food and Drug
Administration Safety and Innovation
Act have been approved under OMB
control number 0910–0661.
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
Dated: October 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–27818 Filed 10–30–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
[Document Identifier: HHS–OS–4040–New–
60D]
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, announces plans
to submit a new Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). Prior to submitting the ICR to
OMB, OS seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
DATES: Comments on the ICR must be
received on or before January 4, 2016.
ADDRESSES: Submit your comments to
Information.CollectionClearance@
hhs.gov or by calling (202) 690–6162.
FOR FURTHER INFORMATION CONTACT:
Information Collection Clearance staff,
Information.CollectionClearance@
hhs.gov or (202) 690–6162.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
document identifier HHS–OS–4040–
New–60D for reference.
Information Collection Request Title:
DATA Act Sec. 5. ‘‘Simplifying Federal
Award Reporting’’ Grants Pilot.
Abstract: Public Law 113–101, The
Digital Accountability and
Transparency Act of 2014 (DATA Act)
expands the Federal Funding
Accountability and Transparency Act of
2006 by increasing accountability and
transparency in Federal spending.
Section 5 of the DATA Act (‘‘Sec. 5.
Simplifying Federal Award Reporting’’)
tasks the Director of the Office of
Management and Budget (OMB) to
establish a pilot program (Sec. 5 (b)).
OMB has designated the Department
of Health and Human Services (HHS) as
the executing agent of the pilot program.
Within HHS, the DATA Act Program
Management Office (PMO) (DAP) has
been established under the Office of the
E:\FR\FM\02NON1.SGM
02NON1
Agencies
[Federal Register Volume 80, Number 211 (Monday, November 2, 2015)]
[Notices]
[Pages 67411-67412]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-27818]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-D-3787]
Information To Support a Claim of Electromagnetic Compatibility
of Electrically Powered Medical Devices; Draft Guidance for Industry
and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the draft guidance entitled ``Information to
Support a Claim of Electromagnetic Compatibility (EMC) of Electrically-
Powered Medical Devices.'' This guidance describes the types of
information that should be provided to support a claim of
electromagnetic compatibility (EMC) in a premarket submission for an
electrically powered medical device. Electromagnetic disturbance is
electronic product radiation that may interfere with the performance of
an electrically powered medical device in its intended environment
(i.e., cause an electromagnetic interference (EMI)). EMC assessment
helps to ensure that a device is able to function in its intended
environment without introducing excessive electromagnetic disturbances
that might interfere with other devices. This draft guidance is not
final nor is it in effect at this time.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment of this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by December 17, 2015.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2015-D-3787 for ``Information to Support a Claim of Electromagnetic
Compatibility (EMC) of Electrically-Powered Medical Devices.'' Received
comments will be placed in the docket and, except for those submitted
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the draft guidance document entitled
``Information to Support a Claim of Electromagnetic Compatibility (EMC)
of Electrically-Powered Medical Devices'' to the Office of the Center
Director, Guidance and Policy Development, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send one self-
addressed adhesive label to assist that office in processing your
request.
[[Page 67412]]
FOR FURTHER INFORMATION CONTACT: Donald Witters, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave. Bldg. 62, Rm. 1130, Silver Spring, MD 20993-0002, 301-796-2483.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of a draft guidance to provide
FDA's current thinking on the types of information that should be
provided in a premarket submission to support a claim of
electromagnetic compatibility for an electrically powered medical
device. EMI is a hazard with associated risk for electrically powered
medical devices. EMC assessment can help to ensure that the risks
associated with performance degradation of electrically powered medical
devices due to EMI are adequately mitigated.
The draft guidance includes information consistent with
specifications described in FDA-recognized consensus national or
international standards for EMC such as in the International
Electrotechnical Commission (IEC) 60601-1-2: Edition 3: 2007-03,
Medical Electrical Equipment--Part 1-2: General Requirements for Basic
Safety and Essential Performance--Collateral Standard: Electromagnetic
Compatibility--Requirements and Tests; IEC 60601-1-2: Edition 4.0:
2014-01, Medical Electrical Equipment, Part 1-2: General Requirements
for Basic Safety and Essential Performance--Collateral Standard:
Electromagnetic Disturbances--Requirements and Tests; Association for
the Advancement of Medical Instrumentation (AAMI)/American National
Standards Institute (ANSI)/IEC 60601-1-2: 2007/(R) 2012 Medical
Electrical Equipment--Part 1-2: General Requirements for Basic Safety
and Essential Performance--Collateral Standard: Electromagnetic
Compatibility--Requirements and Tests; and AAMI/ANSI/IEC 60601-1-2:
2014, Medical Electrical Equipment--Part 1-2: General Requirements for
Basic Safety and Essential Performance--Collateral Standard:
Electromagnetic Disturbances--Requirements and Tests Standards that
sponsors and manufacturers of electrically powered medical devices
often reference. This draft guidance is intended to help ensure that
clear and consistent information is provided in premarket submissions
regarding medical device EMC and to facilitate the review of
submissions with EMC claims.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on information
that should be provided to support claims of electromagnetic
compatibility of electrically powered medical devices. It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by downloading an electronic copy from the Internet. A search
capability for all Center for Devices and Radiological Health guidance
documents is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov. Persons
unable to download an electronic copy of ``Information to Support a
Claim of Electromagnetic Compatibility (EMC) of Electrically-Powered
Medical Devices'' may send an email request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of the document.
Please use the document number 1400057 to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 814 have been approved under
OMB control number 0910-0231. The collections of information in 21 CFR
part 807, subpart E have been approved under OMB control number 0910-
0120. The collections of information in 21 CFR part 812 have been
approved under OMB control number 0910-0078. The collections of
information in 21 CFR part 814, subpart H have been approved under OMB
control number 0910-0332. The collections of information in sections
520(m) and 515A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
360j and 21 U.S.C. 360e-1, respectively) and 613(b) of Food and Drug
Administration Safety and Innovation Act have been approved under OMB
control number 0910-0661.
Dated: October 27, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-27818 Filed 10-30-15; 8:45 am]
BILLING CODE 4164-01-P